BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
From Representative to Business visionary: Private issue Victories - 2Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- 3Opening Achievement: 8 Methodologies for Compelling Using time productively
- 4Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 5This professional Santa's dream of spreading holiday cheer fuels stroke recovery
- US FDA unveils new pathway to approve personalized therapies
- Egypt's cafés and shops forced to close early due to Iran war
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- Flu cases are spiking earlier than usual. What you need to know.
- France to build new nuclear aircraft carrier, Macron says
- 5 Great and High Evaluated Scene Configuration Administrations For 2024
- Why doing good also makes us feel good, during the holidays and beyond
- Iranian president warns of retaliation against Gulf states
